Sign Up to like & get
recommendations!
0
Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2589
Abstract: Although the majority of patients with Hodgkin lymphoma are cured with initial therapy, 10% to 15% of patients with early stage disease and 15% to 30% of patients with advanced disease have primary refractory or…
read more here.
Keywords:
lymphoma;
hodgkin lymphoma;
disease;
lymphoma new ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Blood Cancer Journal"
DOI: 10.1038/s41408-021-00456-w
Abstract: Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus…
read more here.
Keywords:
cell;
lymphoma new;
large cell;
new targets ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "BMJ Open Gastroenterology"
DOI: 10.1136/bmjgast-2019-000320
Abstract: Background Gastrointestinal (GI) lymphomas comprise a group of distinct clinicopathological entities of B- or T- cell type, with primary gastrointestinal Hodgkin lymphoma being extremely uncommon. The GI tract is the predominant site of extranodal non-Hodgkin…
read more here.
Keywords:
lymphoma;
new mimic;
lymphoma new;
site ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0263980
Abstract: The occurrence of MYC-negative Burkitt lymphoma (BL) has been discussed for many years. The real frequency of the MYC insertion in MYC-negative BL is still unknown. Fine-needle aspiration biopsies of 108 consecutive patients with clinicopathologically…
read more here.
Keywords:
cryptic myc;
burkitt lymphoma;
myc insertions;
myc ... See more keywords